Beyond Air (XAIR) Q2 2027 earnings review
Beyond Air hits record sales, but device approval slips into 2027
Beyond Air, the maker of cylinder-free nitric oxide breathing machines for hospitals, posted record sales while its next-generation device slipped past year-end. Revenue grew 28% from a year ago to $2.3 million, and lower engineering costs narrowed the operating loss. Chief executive Robert Goodman kept the calendar 2026 outlook at $8 million, which by our math leaves $2.0 million for the December quarter, down 9% from a year earlier.
| Revenue | $2.3M +28% from a year ago |
|---|---|
| Operating loss | $6.0M $7.7M a year ago |
| Unrestricted core cash | $10.3M $18.5M total reported cash |
| Calendar 2026 and 2027 revenue outlooks | Unchanged $8M for 2026; $16M–$18M for 2027 |
⚖️ Verdict: 🔴 Bearish
The story got worse because regulatory clearance for the second-generation LungFit PH machine pushed into 2027 and rising debt costs erased operating savings. Goodman expects audit readiness in mid-December with FDA inspections after that, pushing back both the transport-capable device launch and $10 million in approval-linked warrant funding. Meanwhile, higher interest expense and scrapped inventory kept the net loss near $8 million against $10 million of unrestricted core cash by our math.
The question now is whether FDA approval arrives early enough in 2027 for Beyond Air to double annual revenue to $16 million–$18 million before needing more capital. If inspections clear quickly in early 2027, the company unlocks $10 million in warrant cash and can sell into larger transport hospitals; if inspections drag, long hospital sales cycles will put the 2027 plan out of reach. The FDA inspection outcome after mid-December will decide it.
🐂 Bull Case
Hospital Demand Lifted Sales to a Record
Beyond Air makes LungFit PH, a machine that generates nitric oxide gas from room air to treat newborns with breathing failure without heavy high-pressure cylinders. After sales barely grew from a year ago in the June quarter, revenue rose 27.8% to a record $2.32 million in the quarter ended September 30.
Sales also jumped 31.4% from the previous three months because the medical device maker signed new hospital contracts and kept existing customers renewing. Gross profit — what remains after the direct cost of making and servicing the machines — turned positive at $0.20 million, compared with a gross loss of $0.30 million a year ago.
What to watch: gross margin in the December quarter after it slipped from 12.7% in the June quarter to 8.5% this period. A rebound above 13% would show that higher hospital usage can cover the frequent 1,000-hour maintenance swap-outs on the first-generation machine.
Lower Development Spending Cut Operating Losses
Beyond Air has been winding down engineering work on the next version of its hospital breathing machine to conserve cash for its sales team. That shift reduced total operating expenses by 16.2% from a year ago to $6.17 million and narrowed the operating loss by 22.0% to $5.98 million.
- Research and development: $1.58 million, down 35.5% from a year ago and down 66.7 percentage points as a share of revenue
- Selling, general and administrative costs: $4.59 million, down 6.6% from a year ago and down 72.7 percentage points of revenue
- Operating loss: $5.98 million, compared with $7.66 million in the prior-year period
The company cut research spending "as the majority of development is complete" on the second-generation LungFit PH system. Lower stock-based pay also trimmed overhead costs, even though the group paid higher sales salaries "as we build out our commercial team" to call on hospitals.
What to watch: quarterly operating expenses in the full transition report for the period ending December 31. Holding quarterly spending near $6 million while preparing for a product launch would prove the current sales staff can handle growth without another hiring wave.
🐻 Bear Case
Second-Generation Device Approval Will Miss 2026
The company's growth plan rests on the second-generation LungFit PH, a lighter machine that adds patient transport by air and ground so Beyond Air can act as a "single-source nitric oxide provider for hospitals and health systems". Earlier this year, leadership aimed for US Food and Drug Administration (FDA) clearance before the end of calendar 2026 and a year-end commercial launch.
"We expect to complete our audit-readiness process in mid-December, and subject to FDA inspections and final approval thereafter," chief executive Robert Goodman said. Because factory inspections and final agency sign-off only happen after mid-December, clearance and commercial sales now push into 2027.
That delay matters because the US medical device group expects the new machine to provide about half of its US revenue in calendar 2027, when its outlook calls for total sales to more than double to $16 million–$18 million.
What to watch: confirmation that the contract manufacturer passed its FDA inspection in early 2027. Any inspection delay past the first quarter of 2027 would leave too little time to win six-to-nine-month hospital sales cycles and hit the 2027 revenue plan.
Full-Year Plan Points to a Fourth-Quarter Dip
"Our US pipeline is now experiencing unprecedented expansion with an acceleration in demand for our first-generation system," chief executive Robert Goodman said. Yet in the same release, Beyond Air left its calendar 2026 revenue target unchanged at $8 million, which includes no sales from the pending second-generation device.
The company already recorded $1.91 million in the March quarter, $1.77 million in the June quarter, and $2.32 million in the September quarter, or $6.00 million across the first nine months of calendar 2026. By our math, an $8 million full-year target leaves $2.00 million for the December quarter — down 13.9% from the September quarter and down 8.8% from the $2.19 million recorded a year earlier.
What to watch: December-quarter revenue in the Form 10-K/T transition report. A drop back toward $2.0 million would show that hospital buyers are waiting for the transport-capable machine rather than accelerating orders for the current model.
Interest Costs and Scrapped Inventory Wiped Out Savings
Even though Beyond Air cut its operating loss by $1.69 million from a year ago, its bottom-line net loss barely budged, moving from $7.94 million to $7.82 million. Non-operating expenses more than tripled from $0.60 million a year ago to $2.20 million, eating up almost all of the operating savings.
The nitric oxide specialist blamed the jump on "an increase in the Company's outstanding debt and related interest expense, in addition to a charge for scrapped materials". Interest and finance costs rose 135.4% from a year ago to $1.50 million, while obsolete inventory at a contract manufacturer cost $0.57 million and debt extinguishment took another $0.25 million.
What to watch: quarterly interest expense and inventory write-offs in the December quarter. With $1.50 million in quarterly financing costs now equal to 64.7% of revenue, net losses will stay near $7 million a quarter even without another inventory write-off.
Debt and Restricted Cash Leave a Thin Cushion
Beyond Air closed the quarter with $18.5 million in total cash, cash equivalents, restricted cash and marketable securities, up from $15.22 million in June after raising funds in July. However, the company does not have free use of that entire balance for its core hospital business.
- Unrestricted cash and securities for parent operations: $10.3 million by our math
- Restricted cash: $4.8 million locked up on the balance sheet
- Subsidiary cash: $2.7 million held by NeuroNOS (now classified as held for sale) and $0.7 million held by Beyond Cancer
- Total debt: $22.04 million ($21.98 million long-term debt plus $0.06 million current loans)
Because the business lost $7.00 million this quarter even before the $0.82 million of debt-extinguishment and inventory charges by our math, $10.3 million of available core liquidity covers less than two quarters of losses at the current rate. Another $10.0 million of warrant funding from the July financing is tied to FDA approval of the second-generation LungFit PH.
What to watch: operating cash burn in the Form 10-Q filing and the timing of the FDA approval warrant trigger. A delay in device approval into 2027 pushes out that $10 million cash inflow while the company prepares to buy launch inventory.
👓 Other Themes
New Partner Takes Over NeuroNOS and Home Device Waits
Beyond Air signed a definitive agreement to sell its controlling stake in neurological unit NeuroNOS Israel Ltd. to UNIVO Pharmaceutical Industries Ltd., replacing an earlier agreement with XTL Biopharmaceuticals and moving $3.02 million of assets to held-for-sale. Separately, the FDA granted Breakthrough Device Designation to LungFit GO, a portable nitric oxide system for nontuberculous mycobacterial lung infection (NTM-PD), but management will not fund it until the second-generation hospital system is established.
💲 Other KPIs
Share count rose more than sixfold from 0.32 million a year ago and nearly tripled from 0.72 million last quarter, adjusted for the 1-for-20 reverse stock split in July 2026. New shares issued in the July financing caused the jump, which mechanically shrank the per-share loss from $24.98 to $3.76 even though total net loss barely changed.
Accounts receivable — money owed by hospitals for delivered systems — rose 27.2% from last quarter to $1.45 million by our math, roughly matching the 31.4% sequential rise in sales. Net inventory fell 7.9% from June to $1.19 million after the company recorded a $0.57 million charge for obsolete materials at its contract manufacturer.
🔮 Guidance
Unchanged. The medical device company kept its calendar 2026 sales plan at $8 million, which excludes any contribution from the second-generation LungFit PH. By our math, subtracting $6.00 million of sales across the first three quarters of calendar 2026 leaves $2.00 million for the December quarter, down 13.9% from the September quarter and down 8.8% from a year earlier.
Unchanged. Beyond Air reaffirmed its calendar 2027 forecast of $16 million to $18 million, which points to 112.5% growth at the middle of the range over the 2026 plan by our math. Achieving that step-up depends on FDA approval and commercial rollout of the transport-capable LungFit PH, whose factory audit readiness now finishes in mid-December with inspections and approval after that.
❓ Key Questions
What caused the $567,000 inventory obsolescence charge?
Beyond Air wrote off $567,000 of inventory at its contract manufacturer in the same quarter it prepared that facility for second-generation FDA audits. Investors need to know whether those scrapped parts belonged to the old machine or reflect design changes on the new model.
What are the financial terms of the UNIVO NeuroNOS sale?
In January 2026, XTL Biopharmaceuticals signed a binding letter to buy 85% of NeuroNOS for $1 million cash, a 19.99% equity stake, and up to $31.5 million in milestones. The release announces a new buyer, UNIVO, without disclosing the cash or equity terms.
When in 2027 does the CY2027 plan assume Gen 2 launches?
With internal audit readiness finishing in mid-December and FDA inspections still ahead, approval will land in 2027. Because hospital sales cycles take six to nine months, management needs to specify the latest approval date that still supports $16 million–$18 million in 2027 revenue.
Why did gross margin drop 4.2 points as revenue hit a record?
Revenue jumped 31.4% from the June quarter to $2.32 million, yet gross margin fell from 12.7% to 8.5% by our math. Management did not say whether higher field service swap-outs, lower hospital pricing, or international distributor mix caused the drop.